LDC7559 |
Catalog No.GC65393
One-Click Copy Product Info
|
LDC7559 is a novel selective inhibitor of Gasdermin D (GSDMD).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2407782-01-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
LDC7559 is a novel selective inhibitor of Gasdermin D (GSDMD)[1]. GSDMD is a pore-forming protein and an executor of pyroptosis[2]. LDC7559 can antagonize the depressive effects of acrylamide (AM) and improve chronic unpredictable mild stress (CUMS) depression in mice[3].
In vitro, pretreatment of A549 cells with LDC7559 (5μM) for 6h significantly reduced the release of intracellular lactate dehydrogenase (LDH) after irradiation and increased cell survival[4]. LDC7559 (10μM) treatment of mouse melanoma B16 cells for 24h significantly inhibited VSV-CHIKV (an oncolytic virus)-induced pyroptosis, reduced the protein level of GSDMD-N (the active form of the pyroptosis executor protein), and inhibited cell membrane rupture[5].
In vivo, LDC7559 (10, 20, 30mg/kg) was intraperitoneally injected into rats with subarachnoid hemorrhage (SAH) model, which alleviated the neurological deficits after SAH, inhibited microglial activation and inflammatory response, and suppressed neuronal pyroptosis and apoptosis as well as GSDMD-mediated signal transduction[6].
References:
[1] Sollberger G, Choidas A, Burn G L, et al. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps[J]. Science immunology, 2018, 3(26): eaar6689.
[2] Pandeya A, Li L, Li Z, et al. Gasdermin D (GSDMD) as a new target for the treatment of infection[J]. Medchemcomm, 2019, 10(5): 660-667.
[3] Liu J F, Han C, Shen J, et al. Acrylamide exposure promotes the progression of depression-like behavior in mice with CUMS via GSDMD-mediated pyroptosis[J]. Ecotoxicology and Environmental Safety, 2025, 289: 117443.
[4] Zhang J, Jiang Z, Liu X, et al. Regulator of G protein signaling 20 contributes to radioresistance of non-small cell lung cancer cells by suppressing pyroptosis[J]. Radiation Medicine and Protection, 2024, 5(3): 178-184.
[5] Wu F, Zhan Y, Wang S, et al. VSV-CHIKV activates antitumor immunity by inducing pyroptosis in a melanoma model[J]. Discover Oncology, 2025, 16(1): 1-15.
[6] Cai W, Wu Z, Lai J, et al. LDC7559 inhibits microglial activation and GSDMD-dependent pyroptosis after subarachnoid hemorrhage[J]. Frontiers in Immunology, 2023, 14: 1117310.
| Cell experiment [1]: | |
Cell lines | A549 cells |
Preparation Method | A549 cells were incubated with 5μM LDC7559 at 6h before irradiation. After 48h of irradiation, the levels of released LDH were detected as indicated. |
Reaction Conditions | 5μM; 6h |
Applications | LDC7559 significantly decreased LDH release in irradiated A549 cells. |
| Animal experiment [2]: | |
Animal models | Sprague-Dawley rats |
Preparation Method | Adult male Sprague-Dawley rats (weighing 230-280g) were used, rat model of subarachnoid hemorrhage (SAH) was built. Before SAH, anesthetization was administered with 1% sodium pentobarbital. A marked filament (4-0) was used to puncture the origin of the left middle cerebral artery. Sham-operated rats received the same treatment, but not with vessel perforation. In vivo experiments, rats were randomly allotted to sham group (n=18), SAH+vehicle group (n=22, 4 animals died), SAH + LDC7559 group (n=60, 6 animals died), and SAH+LDC7559+nigericin group (n=21, 3 animals died). LDC7559 was diluted in 10% DMSO and 90% corn oil before use. LDC7559 (10, 20, or 30mg/kg) or vehicle was treated at 2h after SAH by intraperitoneally administration and then once a day. Nigericin (2mg) was prepared in 2mL ethanol and physiologic saline and was intracerebroventricularly administered at 2h before SAH. |
Dosage form | 10, 20, 30mg/kg; i.p. |
Applications | LDC7559 treatment alleviated neurological deficits after SAH, inhibited microglial activation and inflammatory response, suppressed neuronal pyroptosis and apoptosis, and suppressed GSDMD-mediated signaling. |
References: | |
| Cas No. | 2407782-01-6 | SDF | |
| Formula | C20H19N3O3 | M.Wt | 349.38 |
| Solubility | DMSO : ≥ 125 mg/mL (357.78 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8622 mL | 14.3111 mL | 28.6221 mL |
| 5 mM | 572.4 μL | 2.8622 mL | 5.7244 mL |
| 10 mM | 286.2 μL | 1.4311 mL | 2.8622 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)